

FOI 2204

20.02.2024

FREEDOM OF INFORMATION ACT 2000 – INFORMATION REQUEST

A. How many patients have been treated with the following drugs in the past 4 months:

- **Atogepant (Aquipta) – any disease – Not held**
- **Erenumab (Aimovig) - any disease – 1 patient**
- **Eptinezumab (Vyepiti) – any disease- 2 patients**
- **Fremanezumab (Ajovy) - any disease - 5 patients**
- **Galcanezumab (Emgality) - any disease – 6 patients**
- **Rimegepant (Vydua) – any disease - Not held**
- **Botulinum Toxin (i.e., Botox, Dysport, Xeomin) - migraine ONLY- No specific data for botox issues for Migraine – No direct patient issues – Note Xeomin brand not held**

B. How many patients have you treated in the last 4 months for chronic migraine (15+ headache days per month) and episodic migraine (4-15 headache days per month) with the following drugs:

| Drugs | Chronic Migraine (15+ headache days per month) | Episodic Migraine (4-15 headache days per month) |
|-----------------|--|--|
| Atogepant | | |
| Erenumab | | |
| Eptinezumab | | |
| Fremanezumab | | |
| Galcanezumab | | |
| Rimegepant | | |
| Botulinum Toxin | | |

Information not held

C. Does the trust actively initiate a treatment pause (usually at 12 months) of anti-CGRP (calcitonin gene-related peptide inhibitors) migraine treatment with the aim to re-start treatment if the patient continues to fit the criteria (Yes/No)?

Information not held

Email: Foi.Team@Southerntrust.hscni.net